CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Mayo Clinic
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Dren Bio
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
AVM Biotechnology Inc
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Arovella Therapeutics Ltd
University of Colorado, Denver
Bristol-Myers Squibb
The First Affiliated Hospital of Soochow University
Eastern Cooperative Oncology Group
Medical College of Wisconsin
AstraZeneca
AvenCell Therapeutics, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
Vironexis Biotherapeutics Inc.
Memorial Sloan Kettering Cancer Center
Assistance Publique - Hôpitaux de Paris
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Nurix Therapeutics, Inc.
Thomas Jefferson University
Fate Therapeutics
The Children's Hospital of Zhejiang University School of Medicine
Cellectar Biosciences, Inc.
Center for International Blood and Marrow Transplant Research
Center for International Blood and Marrow Transplant Research
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sellas Life Sciences Group
Caribou Biosciences, Inc.